Median adds six further clinics with the acquisition of ORK


Median Kliniken has acquired private clinic and care home operator ORK (Oberrheinische Kliniken), bringing the total number of clinics in its portfolio to 42 and increasing its annual turnover to over €400million.

The acquisition complements and enhances the scope of Median’s current acute clinic offering in Germany, from both regional and operational perspectives. Having recently expanded its presence in rehabilitation medicine, the company will now strengthen its presence in acute medicine, in particular psychiatry and psychosomatics.

MARCOL Co Founder Mark Steinberg states: “Median is an operator of excellence and the quality leader in the industry, with a strong position to lead the consolidation drive in a very fragmented sector whilst expanding further into acute care. ORK is a well-established and well-managed group and we are very pleased that their capable management team will be joining Median. “

“By strategic acquisition,” adds MARCOL Co Founder Terence Cole, “we are transforming the position of Median to lead the change in the German healthcare market and substantial funds have been committed to support these plans. This acquisition further establishes Median’s leading position in the German healthcare sector and demonstrates the opportunities and ability, together with appropriate considerations and expertise of partners such as Advent International, to complete significant transactions during difficult economic times”.

Median Kliniken was acquired by MARCOL and partners Advent International in 2009. The acquisition of Pitzer Kliniken in 2010 increased the number of clinics from 27 to 36 and the latest acquisition of ORK brings the total number to 42, including two nursing homes. At 28 locations throughout Germany, they consist of over 8,500 beds and employ approx 6,000 staff, providing an extensive range of indications, including psychosomatic, oncology, neurology, geriatrics, orthopaedics and cardiology rehabilitation.

Median was advised by Deloitte and Lovells, who undertook extensive evaluation of the current business and future potential of ORK.

More news >

Recent posts

Terence Cole, our Co-Founder and Joint CEO of MARCOL, sadly passed away on Monday 19 December 2022, after a long illness.

Terence was a larger-than-life character who has left his mark on the world and touched many lives. He was tenacious, a great strategic thinker, …

MARCOL Executive Forum

We recently held our annual MARCOL Executive Forum, bringing together our senior team, and the CEOs and leadership of the MARCOL Portfolio companies: ALMCOR, Atida, …

Creating scalable Healthtech platforms to improve patient access

Published in the 'Global Family Office Community' Journal Article by Ed Radkiewicz, CEO - MARCOL Health   Creating scalable Healthtech platforms to improve …

Thames Enterprise Park wins planning permission for initial 3.7 million sq ft development

Regeneration of former Coryton oil refinery site will create 5,500 new jobs and expected to add £350 million per year to the local economy. Thames …

iSec evolves with new strategy and rebrand as ALMCOR

PRESS RELEASE CEO Jonathan Whittingham looking to widen from industrials into retail, strategic land and first mile logistics as part of diversification and growth Leading …

GoodShape & MARCOL Health innovating in the employee and wellbeing sector

Advertorial in HealthInvestor Publication Innovating in the employee and wellbeing sector Businesses around the world have long struggled to control the impact of employee absence …